Jubiglim M 3mg/500mg Tablet is a combination oral hypoglycemic agent containing Glimepiride 3mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to release insulin, thereby reducing blood glucose levels. Metformin, a biguanide, improves insulin sensitivity by decreasing hepatic glucose production and enhancing peripheral glucose uptake and utilization. The synergistic action of these two agents helps achieve better glycemic control in patients inadequately managed by diet and exercise alone or monotherapy. Jubiglim M is typically prescribed when monotherapy with either agent is insufficient to maintain target blood glucose levels. It is important to monitor blood glucose regularly to adjust dosage appropriately and minimize the risk of hypoglycemia, a potential side effect primarily associated with Glimepiride. Metformin’s common adverse effects include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, which often subside with continued use. This medication should be used cautiously in patients with renal impairment, hepatic dysfunction, or conditions predisposing to hypoxia. Overall, Jubiglim M 3mg/500mg Tablet offers an effective therapeutic option for optimizing glycemic control in type 2 diabetes mellitus when combined lifestyle modifications are insufficient.